Author:
Abulfathi Ahmed Aliyu,Decloedt Eric H.,Svensson Elin M.,Diacon Andreas H.,Donald Peter,Reuter Helmuth
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference170 articles.
1. Petersen E, Blumberg L, Wilson ME, Zumla A. Ending the global tuberculosis epidemic by 2030—the Moscow Declaration and achieving a major translational change in delivery of TB healthcare. Int J Infect Dis. 2017;65:156–8.
2. WHO. Global tuberculosis report 2017. Geneva: WHO Press; 2017.
3. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–95.
4. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: WHO; 2018.
5. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献